Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Raymond James Financial to Strong-Buy Rating

Raymond James Financial upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) from an outperform rating to a strong-buy rating in a research note published on Tuesday, MarketBeat.com reports. They currently have $123.00 price target on the stock, up from their prior price target of $63.00.

DNTH has been the subject of several other research reports. Wedbush boosted their target price on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Robert W. Baird lifted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, HC Wainwright boosted their price target on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics Trading Up 9.7%

Dianthus Therapeutics stock opened at $86.92 on Tuesday. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $86.97. The stock has a market cap of $3.76 billion, a P/E ratio of -21.20 and a beta of 1.56. The stock has a 50 day moving average of $50.09 and a 200-day moving average of $41.61.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 41.34% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Fairmount Funds Management LLC boosted its position in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares during the period. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vanguard Group Inc. raised its stake in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC raised its stake in shares of Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the phase 3 CAPTIVATE CIDP trial after an interim responder analysis — company met GO criteria with 20 confirmed responders and will keep the Part A dose, accelerating development and creating a near‑term catalyst (top‑line CIDP data expected year‑end 2026). Globe Newswire — Early GO Decision
• Positive Sentiment: Encouraging clinical update drove sharp intraday gains — multiple outlets report shares jumped after the interim data and management commentary indicating the program is advancing (investor enthusiasm for a late‑stage autoimmune asset). Investing.com — Stock Surges on CIDP Trial Success
• Positive Sentiment: Multiple analyst upgrades and big price‑target increases (Raymond James to strong‑buy/$123, Robert W. Baird to $132, HC Wainwright to $130, Truist to $110, Guggenheim reiteration) are reinforcing bullish sentiment and providing supporting coverage. Yahoo Finance — Guggenheim Reiterates Buy
• Neutral Sentiment: Analyses and writeups are re‑examining DNTH valuation after large share gains (12–13x over two years); these pieces help frame risk/reward but don’t change near‑term fundamentals. Investors.com — What’s Going On?
• Neutral Sentiment: Company disclosed an AI integration-related cyber/privacy/reputational risk in filings — worth monitoring operationally but not an immediate stock driver versus clinical and financing news. TipRanks — AI Integration Risk
• Negative Sentiment: Announced proposed $400M underwritten public offering (plus 30‑day option for up to $60M) — dilutive capital raise that triggered a stock pullback as investors weigh share issuance against cash runway and program funding. Globe Newswire — $400M Offering
• Negative Sentiment: Q4 earnings missed consensus (loss of $1.43 vs. est. ~$0.97), highlighting ongoing operating losses and the company’s need for external funding — a reminder that clinical progress, not current revenue, is the primary value driver. Zacks — Q4 Loss, Miss

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.